Navigation Links
Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
Date:5/9/2008

WALTHAM, Mass., May 9 /PRNewswire-FirstCall/ -- Inverness Medical Innovations (Amex: IMA) today announced that its previously announced acquisition of Matria Healthcare, Inc. was successfully completed and effective prior to the opening of business today, May 9, 2008. Matria, headquartered in Marietta, Georgia, provides comprehensive, integrated health management services particularly in the areas of women's and children's health, cardiology and oncology. The final purchase price consisted of approximately $143.9 million, and approximately 1.8 million shares of Inverness Series B Convertible Perpetual Preferred Stock (Amex: IMA.PR.B). In addition, existing options to purchase Matria stock have been assumed by Inverness and have converted into options to purchase approximately 1.5 million shares of Inverness common stock.

As a result of the merger, Matria's common stock will no longer trade on The NASDAQ Global Select Market. Pursuant to the merger, each outstanding share of Matria common stock, not owned by Matria or its affiliates and not subject to appraisal rights, has been automatically converted into the right to receive (i) $6.50 in cash, without interest, and (ii) a portion of a share of Series B Preferred Stock of Inverness. Inverness expects that the shares of Series B Preferred Stock will begin trading on the American Stock Exchange LLC as of the opening of the market today, May 9, 2008. The listing approval of the American Stock Exchange LLC for the shares of Series B Preferred Stock is contingent upon Inverness being in compliance with all applicable listing standards on the date it begins trading on the Exchange, and may be rescinded if Inverness is not in compliance with such standards.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts. For additional information on Inverness Medical Innovations, please visit http://www.invernessmedical.com.


'/>"/>
SOURCE Inverness Medical Innovations
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):